8-K: ProMIS Neurosciences Q2 2025: Fast Track & Funding

ProMIS Neurosciences reports Q2 2025 financial results, highlights FDA Fast Track designation for PMN310 in Alzheimer's, and successful capital raise.

Summary

• Net loss for the second quarter ended June 30, 2025, was $10.1 million, compared to $2.6 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $17.46 million, compared to $6.26 million for the same period in 2024.
• Cash and cash equivalents were $4.5 million as of June 30, 2025.
• Subsequent to the quarter, in July 2025, ProMIS received aggregate gross proceeds of $21.6 million from multiple transactions.
• Research and development expenses increased to $8.7 million for Q2 2025, up from $1.6 million in Q2 2024, primarily due to the PRECISE-AD Phase 1b trial.
• General and administrative expenses were $1.4 million for Q2 2025, compared to $1.1 million for Q2 2024.
• PMN310, the lead candidate for Alzheimer's disease, was granted Fast Track Designation by the U.S. FDA in July 2025.
• Enrollment in the PRECISE-AD Phase 1b Alzheimer's disease trial has surpassed 50% of the planned 128 patients as of August 12, 2025.
• No cases of amyloid-related imaging abnormalities (ARIA), including brain swelling or microhemorrhage, have been observed to date in the PRECISE-AD trial, and no patient dropouts have been reported.
• The Data Safety Monitoring Board (DSMB) recommended continuation of the PRECISE-AD trial as planned in May 2025, clearing progression to the 10mg/kg dose level.
• ProMIS expects to report 6-month blinded interim results from PRECISE-AD in 2Q 2026, with final topline results anticipated in 4Q 2026.
• The company's EpiSelectTM Drug Discovery Engine was highlighted at AAIC 2025 for its ability to identify unique conformational epitopes on toxic misfolded proteins.
• Pipeline programs PMN267 for ALS and PMN442 for Parkinson's disease/Multiple System Atrophy are ready to progress to IND-enabling studies.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical and regulatory milestones (Fast Track, no ARIA/dropouts in trial, on schedule progress) and a significant capital raise, which collectively outweigh the increased net loss due to R&D investment. The financial position is strengthened for future development.

Positives

• U.S. FDA granted Fast Track Designation for PMN310 in Alzheimer's disease in July 2025, potentially expediting its development and review.
• The PRECISE-AD Phase 1b trial for PMN310 is progressing on schedule with over 50% enrollment achieved as of August 12, 2025.
• No cases of ARIA (amyloid-related imaging abnormalities) and no patient dropouts have been observed in the PRECISE-AD trial to date, reinforcing PMN310's potential favorable safety profile.
• The DSMB recommended continuation of the PRECISE-AD trial without modification and cleared progression to the next dosing level (10mg/kg).
• Strengthened financial position with $21.6 million in gross proceeds raised in July 2025, providing capital for PMN310's advancement.
• Proprietary EpiSelectTM Drug Discovery Engine continues to identify specific epitopes for neurodegenerative diseases, leading to new candidate antibodies.
• Pipeline candidates PMN267 (ALS) and PMN442 (PD/MSA) are ready to progress to IND-enabling studies, indicating broader pipeline advancement.

Negatives

• Net loss significantly increased to $10.1 million for the second quarter of 2025, compared to $2.6 million for the same period in 2024.
• Research and development expenses increased substantially to $8.7 million for Q2 2025 from $1.6 million for Q2 2024, primarily due to increased clinical trial expenditures.
• Cash and cash equivalents decreased to $4.5 million as of June 30, 2025, from $13.29 million as of December 31, 2024, prior to the July capital raise.
• Accumulated deficit increased to $108.15 million as of June 30, 2025, from $90.69 million as of December 31, 2024.

Risks

• Preclinical results or early clinical results may not be indicative of future results.
• Ability to fund operations and continue as a going concern.
• Accumulated deficit and the expectation for continued losses and future financial results.
• Ability to maintain enough liquidity to execute its business plan.
• Risks associated with clinical trials, including patient enrollment, safety, and efficacy outcomes.

Future Outlook

The company expects to report 6-month blinded interim results from the PRECISE-AD Phase 1b trial in 2Q 2026, with final topline results anticipated in 4Q 2026. PMN267 for ALS and PMN442 for Parkinson's/MSA are ready to progress to IND-enabling studies. The company aims to accelerate PMN310's advancement toward its next phase of development.

Management Comments

• "The team's exceptional focus and execution in the first half of 2025 culminated in what has been an extraordinary past month for ProMIS and its key stakeholders." Neil Warma, Chief Executive Officer.
• "As of August 12, enrollment in the PRECISE-AD Phase 1b Alzheimer's disease trial has surpassed 50% of the planned 128 patients, marking strong recruitment progress." Neil Warma, Chief Executive Officer.
• "Importantly, no cases of amyloid-related imaging abnormalities (ARIA), including brain swelling or microhemorrhage, have been observed to date, and no patient dropouts have been reported, reinforcing PMN310's potential favorable safety profile." Neil Warma, Chief Executive Officer.
• "At this stage, we remain on track to deliver 6-month blinded interim results in 2Q 2026 and final topline results in 4Q 2026." Neil Warma, Chief Executive Officer.
• "In addition, our recent FDA Fast Track designation for PMN310 underscores the urgent need for safer, more effective Alzheimer's treatments." Neil Warma, Chief Executive Officer.
• "Building on this regulatory milestone and the positive clinical progress of PRECISE-AD, we secured approximately $21.6 million in gross proceeds to accelerate PMN310's advancement toward its next phase of development." Neil Warma, Chief Executive Officer.

Industry Context

The granting of Fast Track Designation for PMN310 highlights the significant unmet medical need for safer and more effective treatments for Alzheimer's disease, a major global health challenge. The focus on selectively targeting toxic amyloid-beta oligomers without significant reactivity with amyloid-beta monomers or fibrils positions PMN310 as a potential differentiated therapy in a competitive landscape, aiming to reduce ARIA risk seen with other amyloid-targeting antibodies. The use of advanced biomarkers like plasma pTau217/pT181 for predicting clinical outcomes aligns with broader industry efforts to optimize early-phase drug development in neurodegenerative diseases.

Comparison to Industry Standards

• PMN310's design to selectively target toxic amyloid-beta oligomers while avoiding plaque aims to reduce ARIA risk, a common side effect (brain edema and microhemorrhages) associated with other amyloid-targeting antibodies that bind to vascular/parenchymal amyloid, such as Leqembi (lecanemab) and Aduhelm (aducanumab).
• The absence of ARIA and patient dropouts in the PRECISE-AD Phase 1b trial to date suggests a potentially superior safety profile compared to other amyloid-beta targeting antibodies in early development stages.
• The correlation of group-level plasma pT217 or pT181 with clinical outcome CDR-SB (approximately 0.786 with p values of 0.036) and the Cohens d effect size being three times greater than CDR-SB aligns with industry trends leveraging highly sensitive biomarkers for earlier and more efficient assessment of treatment efficacy, potentially reducing required sample sizes for future trials.

Stakeholder Impact

• Shareholders: Positive impact due to FDA Fast Track designation, positive clinical trial safety data, and successful capital raise, which de-risks the company's financial position and supports future development. Increased net loss is a short-term consequence of increased R&D investment.
• Patients (Alzheimer's): Potential for a safer and more effective treatment option (PMN310) if clinical trials continue to show positive results, especially regarding ARIA reduction.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline.
• Creditors: Improved financial stability due to the recent capital raise, reducing immediate liquidity concerns.

Next Steps

• Continue enrollment and dosing for the PRECISE-AD Phase 1b clinical trial.
• Report 6-month blinded interim results from PRECISE-AD in 2Q 2026.
• Report final topline results from PRECISE-AD in 4Q 2026.
• Progress PMN267 (ALS) and PMN442 (PD/MSA) to IND-enabling studies.
• Accelerate PMN310's advancement toward its next phase of development.

Key Dates

Recommendation

The FDA Fast Track designation for PMN310 significantly de-risks the regulatory pathway for a potentially best-in-class Alzheimer's treatment. The ongoing Phase 1b trial's positive safety profile (no ARIA, no dropouts) and on-schedule progress are highly encouraging, addressing a major concern with current amyloid-targeting therapies. The substantial capital raise of $21.6 million provides critical funding for continued development, alleviating near-term liquidity concerns despite increased R&D expenses. These factors collectively point to strong positive momentum and significant upside potential for the company.

Keywords

ProMIS Neurosciences, PMN, Alzheimer's disease, neurodegenerative diseases, PMN310, Fast Track Designation, clinical trial, Phase 1b, PRECISE-AD, biotechnology, antibody therapeutics, EpiSelect, ALS, Parkinson's disease, financial results, capital raise, biomarkers, ARIA